Abstract Library

#3932 Artisan: Prospective phase II trial of TheraSphere Selective Internal Radiation Therapy (SIRT) for liver metastases in neuroendocrine tumors (NETs)

Introduction: The liver is the commonest site of metastases and is an independent predictor of poor outcome. SIRT allows delivery of high dose radiation to liver metastases and has shown promise in the management of NETs. We determined the safety and efficacy of SIRT in those with inoperable liver metastases in a prospective study.

Conference:

Presenting Author: Ahmed Q

Authors: Ahmed Q, Doumanoglou N, Evans J, Martinez M, Ward C,

Keywords: radioembolization, carcinoid, neuroendocrine, metastases,

#3875 Investigation on dose-toxicity and dose-response relationship in neuroendocrine liver metastases treated with Holmium-166 radioembolization

Introduction: Radioembolization is a viable treatment option for neuroendocrine liver metastases.

Conference:

Presenting Author: Ramdhani K

Authors: Ramdhani K, Verduin J, Smits M, Bruijnen R, Lam M,

Keywords: Radioembolization, SIRT, holmium-166, neuroendocrine liver metastasis,

#3556 Radioembolization of neuroendocrine neoplasms liver metastases: Efficacy and toxicity

Introduction: In patients with unresectable liver metastases, radioembolization has been used to treat tumors from a range of cancers, including neuroendocrine neoplasms.

Conference:

Presenting Author:

Authors: Gola M, Syguła A, Szynkiewicz J, Olczyk T, Kalemba M,

Keywords: radioemolisation liver metastasis,

#3396 Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuro-endocrine tumor liver metastases

Introduction: In radioembolization, response is achieved through the irradiation and damaging of tumor DNA, while treatment toxicity is mainly related to healthy liver dose. Therefore, optimizing the dose in tumors while minimizing the healthy liver dose is deemed important. However, for hepatic metastases of neuroendocrine tumors, a dose-response relationship has not been established yet.

Conference:

Presenting Author: Ebbers S

Authors: Ebbers S, van Roekel C, Braat M, Barentsz M, Lam M,

Keywords: dose-response, neuroendocrine neoplasm, SIRT, 90y, radioembolization, liver metastasis,

#3189 Real-world outcomes of patients with neuroendocrine liver metastases treated with trans-arterial radioembolization: Results from CIRT, a large European prospective multi-centre observational study

Introduction: Trans-arterial radioembolization (TARE) is a treatment option for patients with liver dominant metastases from neuroendocrine tumors (mNET). The CIRSE Registry for SIR-Spheres Therapy (CIRT) is a European prospective multi-centre observational study conducted by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Helmberger T

Authors: Helmberger T, Schaefer N, Pech M, Pfammatter T, Maleux G,

Keywords: liver metastases, observational study, yttrium-90, trans-arterial radioembolization, registry, therapeutic embolization, SIRT,